Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESURGE
NCT07859150Phase 4Not yet recruiting
- Sponsor
- General Authority for Teaching Hospitals and Institutes
- Start
- Oct 2026
- Primary completion
- Apr 2029
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in class III obesity, sponsored by General Authority for Teaching Hospitals and Institutes. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
03
Conditions
class III obesity
Beyond the preview
Go deeper on NCT07859150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859150.